F13.97
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia
Clinical Classification Guidelines
Inclusion Terms
- Sedative, hypnotic, or anxiolytic-induced major neurocognitive disorder, without use disorder
Medical Intelligence & Overview
ICD-10 code F13.97 refers to a type of cognitive decline associated with the long-term use of sedatives, hypnotics, or anxiolytics. This condition involves persistent dementia symptoms that are believed to be caused by these medications, even when they are used as prescribed. Unlike substance use disorder, this diagnosis indicates cognitive impairment resulting from medication effects without problematic usage patterns. Recognizing this condition is important for healthcare providers and patients to manage symptoms effectively and consider alternative treatments.
Causes & Symptoms
Clinical Causes: Prolonged use of sedative medications such as benzodiazepines or sleep aids Chronic use of hypnotic drugs to manage sleep disorders Long-term anxiolytic therapy for anxiety or related conditions Use of these medications in older adults, who may be more vulnerable to cognitive side effects Medication overuse, even if intended for therapeutic reasons
Key Symptoms: Memory loss and difficulty recalling recent events Challenges with problem-solving or planning tasks Reduced ability to concentrate or focus on activities Confusion and disorientation to time or place Difficulty with language or understanding conversations Reduced judgment and decision-making capacity Personality changes or behavioral alterations Progressive decline in daily functioning
Diagnostic & Treatment
Diagnosis Path: Diagnosis of this condition involves a comprehensive review of the patient’s medical history, medication use, and cognitive symptoms. Healthcare professionals may use standardized neurocognitive assessments to evaluate the severity of dementia. Diagnostic criteria focus on the temporal relationship between medication use and cognitive decline, ruling out other potential causes of dementia, such as Alzheimer’s disease or vascular dementia. Blood tests, imaging studies like MRI or CT scans, and neuropsychological testing support the diagnostic process to exclude other conditions.
Treatment Protocols: Management typically involves reviewing and adjusting the patient's medication regimen in collaboration with a healthcare provider. Strategies may include tapering or discontinuing sedatives, hypnotics, or anxiolytics when appropriate. Alternative therapies for sleep and anxiety, such as behavioral therapy or non-pharmacological interventions, might be recommended. Supportive care, cognitive therapy, and creating a safe environment can help improve quality of life. Regular follow-up and monitoring are essential to assess changes in cognitive function and medication effects. Education for patients and caregivers about medication risks is also a vital component of treatment.
Clinical Advice & FAQs
Billing Guidance
Is F13.97 a billable ICD-10 code?
Yes, F13.97 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F13.97?
Clinical documentation must specify the nature of Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference